Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT06839443

Deep Learning in the Detection and Prediction of Hydroxychloroquine Maculopathy

Conditions: Hidroxicloroquine Intake

Sex: All
Ages: 18 Years – 100 Years
Healthy volunteers: Yes
Enrollment: 100
Sponsor: Centro Hospitalar de Lisboa Central

Location: Local de Saúde São José Portugal

Summary

Hydroxychloroquine retinal toxicity affects a significant number of patients using this medication. Detection of toxicity is difficult in the early stages of the disease and depends on the subjectivity of the clinician who reads the tests (optical coherence tomography, autofluorescence and visual fields). Automating the reading of these diagnostic exams could lead to earlier detection of this pathology and reduce the burden associated with interpreting these exams in the ophthalmology service. The images that are usually taken in the screening and monitoring of hydroxychloroquine toxicity by will be collected - photography of the ocular fundus and optical coherence tomography with autofluorescence.

Eligibility Criteria

Inclusion Criteria: * Patients with HCQ intake Exclusion Criteria: * Patients with ocular diseases that might mimic HCQ maculopathy or interfer with HCQ maculopathy screening

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06839443). StuddyBuddy aggregates publicly available trial information.